Literature DB >> 18753339

longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients.

P Randhawa1, D Bohl, D Brennan, K Ruppert, B Ramaswami, G Storch, J March, R Shapiro, R Viscidi.   

Abstract

This study sought to evaluate serology and PCR as tools for measuring BK virus (BKV) replication. Levels of immunoglobulin G (IgG), IgM, and IgA against BKV capsids were measured at five time points for 535 serial samples from 107 patients by using a virus-like particle-based enzyme-linked immunosorbent assay. Viral DNA in urine and plasma samples was quantitated. The seroconversion rate was 87.5% (14/16); 78.6% (11/14) and 14.3% (2/14) of patients who seroconverted developed viruria and viremia, respectively. Transient seroreversion was observed in 18.7% of patients at 17.4 +/- 11.9 weeks posttransplant and was not attributable to loss of antigenic stimulation, changes in immunosuppression, or antiviral treatment. Titers for anti-BK IgG, IgA, and IgM were higher in patients with BKV replication than in those without BKV replication. A rise in the optical density (OD) of anti-BK IgA (0.19), IgM (0.04), or IgG (0.38) had a sensitivity of 76.6 to 88.0% and a specificity of 71.7 to 76.1% for detection of viruria. An anti-BK IgG- and IgA-positive phenotype at week 1 was less frequent in patients who subsequently developed viremia (14.3%) than in those who subsequently developed viruria (42.2%) (P = 0.04). Anti-BK IgG OD at week 1 showed a weak negative correlation with peak urine viral load (r = -0.25; P = 0.05). In summary, serial measurements of anti-BKV immunoglobulin class (i) detect onset of viral replication, (ii) document episodes of seroreversion, and (iii) can potentially provide prognostic information.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753339      PMCID: PMC2565927          DOI: 10.1128/CVI.00206-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

1.  Nephropathy due to polyomavirus type BK.

Authors:  P S Randhawa; A J Demetris
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy.

Authors:  H H Hirsch; M Mohaupt; T Klimkait
Journal:  J Infect Dis       Date:  2001-12-01       Impact factor: 5.226

3.  BK virus infection in AIDS.

Authors:  O Cubukcu-Dimopulo; A Greco; A Kumar; D Karluk; K Mittal; J Jagirdar
Journal:  Am J Surg Pathol       Date:  2000-01       Impact factor: 6.394

4.  A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation.

Authors:  S Cesaro; C Facchin; G Tridello; C Messina; E Calore; M A Biasolo; M Pillon; S Varotto; A Brugiolo; C Mengoli; G Palù
Journal:  Bone Marrow Transplant       Date:  2007-11-05       Impact factor: 5.483

5.  Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus.

Authors:  R S Hamilton; M Gravell; E O Major
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy.

Authors:  V Nickeleit; T Klimkait; I F Binet; P Dalquen; V Del Zenero; G Thiel; M J Mihatsch; H H Hirsch
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

7.  Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients.

Authors:  F Smets; M Bodeus; P Goubau; R Reding; J B Otte; J P Buts; E M Sokal
Journal:  J Hepatol       Date:  2000-01       Impact factor: 25.083

8.  The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion".

Authors:  M V Ragni; O K Ndimbie; E O Rice; F A Bontempo; S Nedjar
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

9.  Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients.

Authors:  F Ginevri; A Azzi; H H Hirsch; S Basso; I Fontana; M Cioni; S Bodaghi; V Salotti; A Rinieri; G Botti; F Perfumo; F Locatelli; P Comoli
Journal:  Am J Transplant       Date:  2007-10-01       Impact factor: 8.086

10.  Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.

Authors:  Melanie Hart; Alan Steel; Sally A Clark; Graeme Moyle; Mark Nelson; Don C Henderson; Robert Wilson; Frances Gotch; Brian Gazzard; Peter Kelleher
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

View more
  20 in total

1.  Inhibitory interactions between BK and JC virus among kidney transplant recipients.

Authors:  Xingxing S Cheng; Daniel L Bohl; Gregory A Storch; Caroline Ryschkewitsch; Monique Gaudreault-Keener; Eugene O Major; Parmjeet Randhawa; Karen L Hardinger; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  BK polyomavirus infection and nephropathy: the virus-immune system interplay.

Authors:  Nina Babel; Hans-Dieter Volk; Petra Reinke
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

3.  Prospective Study of Human Polyomaviruses and Risk of Cutaneous Squamous Cell Carcinoma in the United States.

Authors:  Anala Gossai; Tim Waterboer; Heather H Nelson; Jennifer A Doherty; Angelika Michel; Martina Willhauck-Fleckenstein; Shohreh F Farzan; Brock C Christensen; Anne G Hoen; Ann E Perry; Michael Pawlita; Margaret R Karagas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-11       Impact factor: 4.254

Review 4.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

5.  Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.

Authors:  P Randhawa; D V Pastrana; G Zeng; Y Huang; R Shapiro; P Sood; C Puttarajappa; M Berger; S Hariharan; C B Buck
Journal:  Am J Transplant       Date:  2015-03-03       Impact factor: 8.086

6.  Quantitation of human seroresponsiveness to Merkel cell polyomavirus.

Authors:  Diana V Pastrana; Yanis L Tolstov; Jürgen C Becker; Patrick S Moore; Yuan Chang; Christopher B Buck
Journal:  PLoS Pathog       Date:  2009-09-11       Impact factor: 6.823

7.  Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma.

Authors:  Hélène C Laude; Barbara Jonchère; Eve Maubec; Agnès Carlotti; Eduardo Marinho; Benoit Couturaud; Martine Peter; Xavier Sastre-Garau; Marie-Françoise Avril; Nicolas Dupin; Flore Rozenberg
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

8.  Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients.

Authors:  Sohrab Bodaghi; Patrizia Comoli; Robert Bösch; Alberta Azzi; Rainer Gosert; David Leuenberger; Fabrizio Ginevri; Hans H Hirsch
Journal:  J Clin Microbiol       Date:  2009-05-27       Impact factor: 5.948

9.  Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons.

Authors:  Christian Wüthrich; Xin Dang; Susan Westmoreland; John McKay; Atul Maheshwari; Matthew P Anderson; Allan H Ropper; Raphael P Viscidi; Igor J Koralnik
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

10.  Serological evidence of an early seroconversion to Simian virus 40 in healthy children and adolescents.

Authors:  Angelo Taronna; Elisa Mazzoni; Alfredo Corallini; Ilaria Bononi; Silvia Pietrobon; Giovanni Guerra; Caterina Palmonari; Caterina Borgna-Pignatti; Manola Comar; Massimo Bovenzi; Ferruccio Casali; Roberto Marci; Giovanni Rezza; Giuseppe Barbanti-Brodano; Mauro Tognon; Fernanda Martini
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.